Epigenetics within the tumor microenvironment

Guest Editor: Aamir Ahmad – Mitchell Cancer Institute, AL, USA

Advances in our understanding of tumor progression and relapse have underlined the importance of tumor microenvironment, which comprises components within the immediate vicinity of tumor cells such as fibroblasts, immune cells and the extracellular matrix. The exact way in which tumor microenvironment affects metastatic spread and acquired resistance to therapy is not fully understood, but accumulating evidence suggests epigenetic mechanisms are involved. This Collection invites original research focusing on epigenetic changes in tumor cells and their surrounding microenvironment.
Submissions will be welcomed at any point up until the end of August 2019. For information regarding Scientific Reports' policies on Guest Edited Collections please read this page.
To submit your manuscript for consideration at Scientific Reports as part of this Collection, please follow the steps detailed on this page. On the first page of our online submission system, in the first drop-down menu, named “Type”, select “Guest Edited Collections”. Then when filling out the manuscript information, select the "Epigenetics within the tumor microenvironment" Collection from the alphabetical list on the “Springer Nature Subject Category” tab. Authors should express their interest in the Collection in their cover letter.
In addition to papers on epigenetics within the tumor environment, Scientific Reports welcomes all original research in the field of cancer. To browse our latest articles in cancer, click here.
 

About the Guest Editor

  Aamir Ahmad holds a PhD in Biochemistry from AMU, India, and completed his post-doctoral training at the NCI, NIH, MD, USA. He is currently a research faculty at Mitchell Cancer Institute, AL, USA. Dr Ahmad’s research investigates the epigenetic basis of cancer drug resistance and metastasis, with a focus on non-coding RNAs, cancer stem cells and the tumor microenvironment. He has been serving on the Cancer section of Scientific Reports’ Editorial Board since 2017.